Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 4, 2026

We're 6 Weeks Away From a Historic Change at the Federal Reserve -- and It May Be the Tipping Point for a Pricey Stock Market

View original at nasdaq.com
We're 6 Weeks Away From a Historic Change at the Federal Reserve -- and It May Be the Tipping Point for a Pricey Stock Market Key Points Jerome Powell's second term as Fed chair will conclude on May 15…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Warsh's potential appointment may represent the tipping point for a historically expensive stock market

    60% confidence
  • Kevin Warsh would prefer the central bank be a passive market participant, entailing selling off significant chunks of Treasury bonds and/or mortgage-backed securities

    60% confidence
  • His voting record strongly suggests he won't push for aggressive rate cuts

    60% confidence
  • Trump has vocally criticized Powell and the FOMC for not being more aggressive in lowering interest rates

    60% confidence
  • Trump prefers the federal funds rate be 1% or lower, compared with the current range of 3.50% to 3.75%

    60% confidence
  • Warsh remained persistently skeptical of inflation and often advocated that interest rates remain elevated even as unemployment rose during the financial crisis

    60% confidence
  • The stock market entered 2026 at its second-priciest valuation since January 1871, according to the S&P 500's Shiller Price-to-Earnings Ratio

    60% confidence
  • Lower interest rates would make it considerably easier for the U.S. to service its ever-growing national debt and would reduce borrowing costs for businesses

    60% confidence
  • Rate hikes now seem more likely than rate cuts in 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com